Jose Torrealba

Prof. Dr. Jose Torrealba

Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Human Pathology
Verified
Journal Article
Closed access
Jose TorrealbaJose Torrealba
Jose Torrealba
SFStephen Fisher
Stephen Fisher
JKJeffrey P. Kanne
Jeffrey P. Kanne
YBYasmeen M. Butt
Yasmeen M. Butt
CGCraig Glazer
Craig Glazer
KBKiran Batra
Kiran Batra

31 January 2017 in Journal of Comparative Physiology B
Verified
Journal Article
Closed access
PDF file
JOJessica P. Otis
Jessica P. Otis
APAmanda C. Pike
Amanda C. Pike
Jose TorrealbaJose Torrealba
Jose Torrealba
HCHannah V. Carey
Hannah V. Carey

1 September 2017 in Investigative Radiology
Verified
Journal Article
Open access
DCDaniel Costa
Daniel Costa
YCYonatan Bsmed Chatzinoff
Yonatan Bsmed Chatzinoff
NPNiccolo M. Passoni
Niccolo M. Passoni
PKPayal Kapur
Payal Kapur
CRClaus G. Roehrborn
Claus G. Roehrborn
RCRajiv Chopra
Rajiv Chopra
Objectives: The aim of this study was to compare the anatomical registration of preoperative magnetic resonance imaging (MRI) and prostate whole-mount obtained with 3D-printed, patient-specific, MRI-derived molds (PSM) versus conventional whole-mount sectioning (WMS). Materials and Methods: Based on an a priori power analysis, this institutional review board–approved study prospectively included 50 consecutive men who underwent 3 T multiparametric prostate MRI followed by radical prostatectomy. Two blinded and independent readers (R1 and R2) outlined the contours of the prostate, tumor, peripheral, and transition zones in the MRI scans using regions of interest. These were compared with the corresponding regions of interest from the whole-mounted histopathology, the reference standard, using PSM whole-mount results obtained in the study group (n = 25) or conventional WMS in the control group (n = 25). The spatial overlap across the MRI and histology data sets was calculated using the Dice similarity coefficient (DSC) for the prostate overall (DSCprostate), tumor (DSCtumor), peripheral (DSCPZ), and transition (DSCTZ) zone. Results in the study and control groups were compared using Wilcoxon rank sum test. Results: The MRI histopathology anatomical registration for the prostate gland overall, tumor, peripheral, and transition zones were significantly superior with the use of PSMs (DSCs for R1: 0.95, 0.86, 0.84, and 0.89; for R2: 0.93, 0.75, 0.78, and 0.85, respectively) than with the use of standard WMS (R1: 0.85, 0.46, 0.66, and 0.69; R2: 0.85, 0.46, 0.66, and 0.69) (P < 0.0001). Conclusions: The use of PSMs for prostate specimen whole-mount sectioning provides significantly superior anatomical registration of in vivo multiparametric MRI and ex vivo prostate whole-mounts than conventional WMS.

1 May 2020 in Seminars in Diagnostic Pathology
Verified
Journal Article
Closed access
CMChristopher Metter
Christopher Metter
Jose TorrealbaJose Torrealba
Jose Torrealba

23 November 2009 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
ADArjang Djamali
Arjang Djamali
MSMillie Samaniego
Millie Samaniego
Jose TorrealbaJose Torrealba
Jose Torrealba
JPJohn Pirsch
John Pirsch
BMBrenda L Muth
Brenda L Muth
Background. There is no information on the effects of proteinuria on outcomes following rejection.

23 November 2021 in JCR: Journal of Clinical Rheumatology
Verified
Journal Article
Open access
EJElena Joerns
Elena Joerns
TATraci N. N Adams
Traci N. N Adams
CNChad Newton
Chad Newton
BBBonnie Bermas
Bonnie Bermas
DKDavid Karp
David Karp
UMUna E. Md Makris
Una E. Md Makris
Background/Objective: We have limited knowledge regarding characteristics of patients with interstitial pneumonia with autoimmune features (IPAF) that are associated with response to immunosuppression. In this study, we used published IPAF criteria to characterize features associated with response to treatment. Methods: We conducted a single-center medical records review study of 63 IPAF patients to evaluate for serological, clinical, and morphological characteristics that are associated with response to immunosuppression. Response was defined as % relative functional vital capacity decline of less than 10% and absence of death or lung transplant within the first year of continuous immunosuppressive therapy. Nonparametric measures of association and multivariate logistic regression were used to evaluate the relationship between baseline characteristics and immunosuppressive response. Results: There was a trend of greater progression among men, ever smokers, those negative for antisynthetase antibodies, and those with usual interstitial pneumonia radiographic pattern, but no statistically significant relationship was found between baseline serological, clinical, or morphological features and response to immunosuppression. Patients on combination therapy with mycophenolate mofetil and prednisone had less disease progression (p = 0.018) than those on regimens that did not include both of these medications. Conclusions: In our cohort, baseline clinical assessment did not identify which patients with IPAF will respond to immunosuppressive therapy. Combination therapy with mycophenolate mofetil and prednisone was associated with lack of disease progression in our IPAF patients, including in IPAF–usual interstitial pneumonia. Further studies are needed to evaluate which IPAF patients would benefit from immunosuppressive therapy, antifibrotic therapy, or a combination of both.